Apoprotein B-100 Production Is Decreased in Subjects Heterozygous for Truncations of Apoprotein B
- 1 January 1995
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 15 (1) , 71-80
- https://doi.org/10.1161/01.atv.15.1.71
Abstract
Abstract Among individuals who are heterozygous for familial hypobetalipoproteinemia (FHBL) and who have various truncations of apoprotein (apo) B (ie, FHBL with apoB truncation/apoB-100 genotypes), the plasma concentrations of apoB-100 are typically ≈30% rather than the expected ≈50% of those in unaffected family members. The metabolic basis for the low apoB-100 levels is unknown. Therefore, we compared the metabolism of apoB-100 in 8 subjects with heterozygous FHBL (2 apoB-89/apoB-100, 2 apoB-75/apoB-100, 2 apoB-54.8/apoB-100, 1 apoB-52/apoB-100, and 1 apoB-31/apoB-100) with the metabolism of apoB-100 in 8 apoB-100/apoB-100 control subjects who were paired with the heterozygotes by gender, age, height, weight, and race. Endogenous labeling of apoB-100 with [ 13 C]leucine and a multicompartmental kinetic model were used to obtain kinetic parameters. FHBL heterozygotes had significantly reduced VLDL apoB-100 production rates (7.7±3.7 versus 21.2±6.2 mg · kg −1 · d −1 , P =.002) and LDL apoB-100 production rates (4.5±3.12 versus 15.3±1 mg · kg −1 · d −1 , P =.05) compared with control subjects. Fractional conversion rates of VLDL to LDL were not significantly different (0.67±0.36 versus 0.77±0.17 pools/d), and the respective fractional catabolic rates of apoB-100 in VLDL, IDL, and LDL also were similar in both groups. Thus, FHBL heterozygotes produced apoB-100 at about 30% of the rates of control subjects. We believe these reduced production rates largely account for the lower than expected levels of apoB-100 and LDL cholesterol in the plasma of FHBL heterozygotes.Keywords
This publication has 31 references indexed in Scilit:
- George Lyman Duff Memorial Lecture. Multifactorial etiology of hypercholesterolemia. Implications for prevention of coronary heart disease.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991
- Familial hypobetalipoproteinemia caused by a mutation in the apolipoprotein B gene that results in a truncated species of apolipoprotein B (B-31). A unique mutation that helps to define the portion of the apolipoprotein B molecule required for the formation of buoyant, triglyceride-rich lipoproteins.Journal of Clinical Investigation, 1990
- Oleic acid stimulation of apolipoprotein B secretion from HepG2 and Caco-2 cells occurs post-transcriptionallyBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1989
- Familial Hypobetalipoproteinemia Associated with a Mutant Species of Apolipoprotein B (B-46)New England Journal of Medicine, 1989
- Genetic analysis of a kindred with familial hypobetalipoproteinemia. Evidence for two separate gene defects: one associated with an abnormal apolipoprotein B species, apolipoprotein B-37; and a second associated with low plasma concentrations of apolipoprotein B-100.Journal of Clinical Investigation, 1987
- Development of an integrated model for analysis of the kinetics of apolipoprotein B in plasma very low density lipoproteins, intermediate density lipoproteins, and low density lipoproteins.Journal of Clinical Investigation, 1985
- Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects.Journal of Clinical Investigation, 1984
- Metabolic Studies in an Unusual Case of Asymptomatic Familial Hypobetalipoproteinemia with Hypoalphalipoproteinemia and Fasting ChylomicronemiaJournal of Clinical Investigation, 1979
- A deconvolution schemeMathematical Biosciences, 1978
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970